ARTICLE | Company News

FDA reviewing Acacia's PONV therapy

January 4, 2018 8:03 AM UTC

Acacia Pharma Group Ltd. (Cambridge, U.K.) said FDA accepted for review an NDA for Baremsis amisulpride (formerly APD421), alone and in combination with other antiemetics, as treatment and prophylaxis for postoperative nausea and vomiting. The PDUFA date is Oct. 5.

Baremsis is a low-dose IV formulation of amisulpride, an off-patent dopamine D2 and D3 receptor (DRD3) antagonist. ...

BCIQ Company Profiles

Acacia Pharma Group plc